110 related articles for article (PubMed ID: 30523991)
1. Development of a novel drug targeting delivery system for cervical cancer therapy.
Xiao L; Ma N; He H; Li J; Cheng S; Yang Q; Hou Y; Song F; Jin H; Su X; Dong J; Zuo R; Song X; Duan W; Hou Y
Nanotechnology; 2019 Feb; 30(7):075604. PubMed ID: 30523991
[TBL] [Abstract][Full Text] [Related]
2. Screening and identification of a specific peptide binding to cervical cancer cells from a phage-displayed peptide library.
Li C; Gao N; Xue Q; Ma N; Hu Y; Zhang J; Chen B; Hou Y
Biotechnol Lett; 2017 Oct; 39(10):1463-1469. PubMed ID: 28634746
[TBL] [Abstract][Full Text] [Related]
3. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
5. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
[TBL] [Abstract][Full Text] [Related]
6. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
7. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
8. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
9. A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy.
Xiao L; Hou Y; He H; Cheng S; Hou Y; Jin H; Song X; Nie G; Hou Y
Nanoscale; 2020 Aug; 12(32):17029-17044. PubMed ID: 32780053
[TBL] [Abstract][Full Text] [Related]
10. Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy.
Wang SH; Lee AC; Chen IJ; Chang NC; Wu HC; Yu HM; Chang YJ; Lee TW; Yu JC; Yu AL; Yu J
Biomaterials; 2016 Jul; 94():31-44. PubMed ID: 27088408
[TBL] [Abstract][Full Text] [Related]
11. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
12. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
13. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel microbubble-liposome complex conjugated with peptide ligands targeting IL4R on brain tumor cells.
Park SH; Yoon YI; Moon H; Lee GH; Lee BH; Yoon TJ; Lee HJ
Oncol Rep; 2016 Jul; 36(1):131-6. PubMed ID: 27220374
[TBL] [Abstract][Full Text] [Related]
15. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
[TBL] [Abstract][Full Text] [Related]
18. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
Shi NQ; Li Y; Zhang Y; Shen N; Qi L; Wang SR; Qi XR
ACS Appl Mater Interfaces; 2017 Dec; 9(48):41767-41781. PubMed ID: 29161013
[TBL] [Abstract][Full Text] [Related]
19. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.
Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L
Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
